Article
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
British journal of cancer - 9 Jun 2015
Rowland A, Dias M M, Wiese M D, Kichenadasse G, McKinnon R A, Karapetis C S, Sorich M J
Abstract excerpt
BACKGROUND: Metastatic colorectal cancer (mCRC) that harbours a BRAF V600E mutation (BRAF MT) is associated with poorer outcomes. However, whether this mutation is predictive of treatment benefit from anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) is uncertain. METHODS: We conducted a systematic review and meta-analysis of randomised controlled trials (RCTs) published up to July 2014...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.